Comparison and Evaluation of Efficacy and Safety of Sitagliptin and Linagliptin in Adults With Type 2 Diabetes Mellitus: A Bayesian Network Meta-Analysis - PubMed
10 hours ago
- #DPP-4 Inhibitors
- #Type 2 Diabetes
- #Network Meta-Analysis
- A Bayesian network meta-analysis of 87 RCTs with 64,517 participants compares sitagliptin 100 mg/day and linagliptin 5 mg/day for adults with type 2 diabetes mellitus.
- Both drugs significantly reduce HbA1c and fasting plasma glucose compared to placebo, with no significant differences in efficacy between them.
- Safety profiles show no significant increase in adverse events for either drug versus placebo, and no significant differences in most safety outcomes between them.
- The analysis included a primary analysis of 61 RCTs (28,715 participants) at 24-54 weeks, using Bayesian random-effects models and assessing bias and evidence certainty.
- Conclusions indicate equivalent efficacy and safety for both drugs, with neither significantly superior to other included antidiabetic drugs for glycemic control.